Specific Cellular and Humoral Response after the Third Dose of Anti-SARS-CoV-2 RNA Vaccine in Patients with Immune-Mediated Rheumatic Diseases on Immunosuppressive Therapy.
Kauzar Mohamed MohamedMaría Paula Álvarez-HernándezCarlos Jiménez GarcíaKissy Guevara-HoyerDalifer FreitesCristina Martínez PradaInés Pérez-SancristóbalBenjamín Fernández GutiérrezGloria Mato ChaínMaria RoderoAntonia Rodríguez de la PeñaTeresa MuleroCecilia BravoEsther ToledanoEsther Culebras LópezBeatriz Mediero ValerosPedro Pérez SeguraSilvia Sánchez-RamónGloria Candelas RodríguezPublished in: Biomedicines (2023)
Our preliminary data show that the majority of our IMRD patients develop cellular and humoral responses after the SARS-CoV-2 booster vaccination, emphasizing the relevance of vaccination in this group. However, the magnitude of specific responses was dependent on the immunosuppressive therapy administered. Specific vaccination protocols and personalized decisions about boosters are essential for these patients.